47.29
price up icon2.25%   +1.04
after-market  After Hours:  47.29 
loading
Sanofi ADR stock is currently priced at $47.29, with a 24-hour trading volume of 2.58M. It has seen a +2.25% increased in the last 24 hours and a -2.84% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $46.33 pivot point. If it approaches the $47.72 resistance level, significant changes may occur.
Previous Close:
$46.25
Open:
$46.69
24h Volume:
2.58M
Market Cap:
$118.32B
Revenue:
$50.69B
Net Income/Loss:
$4.95B
P/E Ratio:
14.90
EPS:
3.1735
Net Cash Flow:
$19.70B
1W Performance:
-3.21%
1M Performance:
-2.84%
6M Performance:
-0.82%
1Y Performance:
-9.13%
1D Range:
Value
$46.37
$47.31
52W Range:
Value
$42.63
$55.72

Sanofi ADR Stock (SNY) Company Profile

Name
Name
Sanofi ADR
Name
Phone
33 1 53 77 40 00
Name
Address
54, Rue La Boétie, Paris
Name
Employee
106,566
Name
Twitter
@sanofi
Name
Next Earnings Date
2024-05-22
Name
Latest SEC Filings
Name
SNY's Discussions on Twitter

Sanofi ADR Stock (SNY) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-23-24 Initiated Morgan Stanley Equal-Weight
Jan-16-24 Resumed UBS Buy
Dec-05-23 Downgrade JP Morgan Overweight → Neutral
Oct-30-23 Downgrade Stifel Buy → Hold
Sep-06-23 Upgrade Berenberg Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Apr-28-23 Downgrade Deutsche Bank Hold → Sell
Mar-27-23 Upgrade Barclays Equal Weight → Overweight
Dec-13-22 Resumed Morgan Stanley Overweight
Aug-12-22 Upgrade Deutsche Bank Sell → Hold
Aug-09-22 Downgrade UBS Buy → Neutral
May-23-22 Initiated SVB Leerink Outperform
Sep-27-21 Upgrade SVB Leerink Mkt Perform → Outperform
Jan-15-21 Initiated Deutsche Bank Sell
Sep-29-20 Initiated Berenberg Hold
Mar-17-20 Upgrade Barclays Underweight → Equal Weight
Mar-11-20 Upgrade Goldman Neutral → Buy
Feb-11-20 Initiated SVB Leerink Mkt Perform
Jan-06-20 Upgrade JP Morgan Neutral → Overweight
Sep-23-19 Upgrade Guggenheim Neutral → Buy
Sep-20-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-03-19 Initiated Bernstein Outperform
Aug-14-19 Upgrade UBS Neutral → Buy
Dec-11-18 Upgrade Jefferies Hold → Buy
Nov-01-18 Upgrade Barclays Underweight → Equal Weight
Oct-09-18 Initiated Guggenheim Neutral
Sep-10-18 Upgrade BofA/Merrill Neutral → Buy
Aug-10-18 Upgrade Citigroup Neutral → Buy
Mar-23-18 Upgrade Liberum Hold → Buy
Jan-23-18 Downgrade Barclays Equal Weight → Underweight
Dec-06-17 Downgrade BofA/Merrill Buy → Neutral
Dec-01-17 Downgrade Morgan Stanley Overweight → Underweight
Nov-15-17 Upgrade Barclays Underweight → Equal Weight
Aug-30-17 Upgrade HSBC Securities Reduce → Hold
View All

Sanofi ADR Stock (SNY) Financials Data

Sanofi ADR (SNY) Revenue 2024

SNY reported a revenue (TTM) of $50.69 billion for the quarter ending March 31, 2024, a +5.47% rise year-over-year.
loading

Sanofi ADR (SNY) Net Income 2024

SNY net income (TTM) was $4.95 billion for the quarter ending March 31, 2024, a -42.92% decrease year-over-year.
loading

Sanofi ADR (SNY) Cash Flow 2024

SNY recorded a free cash flow (TTM) of $19.70 billion for the quarter ending June 30, 2023.
loading

Sanofi ADR (SNY) Earnings per Share 2024

SNY earnings per share (TTM) was $1.9785 for the quarter ending March 31, 2024, a -29.06% decline year-over-year.
loading
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; and Allegra for seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. Sanofi has strategic alliance with Sensile Medical Ltd.; collaboration with Evotec AG; and partnership with REVOLUTION Medicines, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
drug_manufacturers_general PFE
$26.98
price down icon 2.00%
drug_manufacturers_general BMY
$40.97
price down icon 0.56%
drug_manufacturers_general GSK
$40.66
price up icon 0.02%
$303.28
price up icon 1.56%
drug_manufacturers_general NVS
$104.93
price down icon 0.75%
Cap:     |  Volume (24h):